Arena third one fourth net loss raises to $36.

For the commercialization of lorcaserin in the usa following FDA authorization of the NDA for lorcaserin. Beneath the terms of the contract, Arena received a non-refundable, upfront payment of $50.0 million from Eisai. Related StoriesBetalin launches fresh EMP technology that could transform diabetes treatmentBariatric medical procedures improves pounds, metabolic health and standard of living in adolescents after 3 yearsObesity groups take purpose at claims that deny coverage of weight problems treatment under affordable care actOther Announced that following completion of a Stage 1 clinical trial plan for APD597, Ortho-McNeil-Janssen Pharmaceuticals, Inc., didn’t advance APD597 and notified Arena that it is terminating their collaboration, december 28 effective, 2010.Kaiser Health News, an editorially independent information service, is a program of the Kaiser Family members Foundation, a nonpartisan healthcare policy research business unaffiliated with Kaiser Permanente.. Axel Ullrich receives this year’s 2009 Dr. Paul Janssen Award for Biomedical Research Today honored the profession achievements of Axel Ullrich Johnson & Johnson, Ph.D., with this year’s 2009 Dr. Paul Janssen Award for Biomedical Study. Dr. Ullrich received this award for his scientific discoveries that resulted in innovative new medicines including Herceptin) *, a personalized medication therapy, which was the first ever to target a particular type of breast tumor.

Related Posts

Other Posts From Category "ozone therapy":